Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...

Patients with oligometastatic lung cancer may live longer with surgery, but experts stress the need for multidisciplinary ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...

Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...

Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, ...

Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

Corcept's ALS drug dazucorilant improved survival despite missing the main goal; ovarian cancer drug combo met its target in ...

Mutations in the PIK3CA gene are a key driver of breast cancer and are present in 35–40% of hormone receptor–positive breast ...